The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

NCT07583862 | Not Yet Recruiting Phase 2 FDA Drug

• 1 other identifier: Effects of Timolol Mohs Scalp
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study clinical trial is to learn if topical timolol can accelerate healing and improve the cosmetic appearance of surgical wounds on the scalp following Mohs surgery. It will include Geisinger patients 18 year or older who undergo Mohs surgery of the scalp with planned wound healing by secondary intent. The main questions in aim to answer are:

1. 1.Compare wound healing speed between patients treated with topical timolol and those receiving standard wound care only.
2. 2.Compare cosmetic outcomes using topical timolol and standard wound care.
3. 3.Evaluate the impact of topical timolol on the number of unplanned follow-up visits and calls related to delayed wound healing.

Conditions

Surgical Wounds; Mohs Surgery

Keywords

Mohs surgery; wound healing; wound granulation; timolol; scar cosmesis; scars

Outcome Measures

Primary Outcomes (2)

• Healing At 12 Weeks

  Percentage of patients achieving complete re-epithelialization at 12 weeks

  From treatment start to follow up 12 weeks later

• Scar Cosmesis

  Scar cosmesis calculated using visual analog scale (VAS)

  Calculated at 4, 8, and 12 week follow up after treatment start.

Secondary Outcomes (5)

• Healing At 8 Weeks

  From treatment start to follow up 8 weeks later

• Healing At 4 Weeks

  From treatment start to follow up 4 weeks later

• Change In Wound Area at Follow Up

  Calculated at 4, 8, and 12 week follow up after treatment start.

• Calls for Non-healing Wounds

  From treatment start to 12 weeks.

• Visits for Non-healing Wounds

  From treatment start to 12 weeks.

Study Arms (2)

Timolol Arm

ACTIVE COMPARATOR

This arm will have their wounds treated with topical timolol.

Drug: Topical Timolol

Standard of Care Arm

PLACEBO COMPARATOR

This arm will have their wounds treated with normal saline/standard of care.

Drug: Normal Saline

Interventions

Topical Timolol DRUG

Topical timolol is the active drug that will be compared to placebo in the trial.

Timolol Arm

Normal Saline DRUG

Normal saline is the placebo that will be compared to topical timolol in the trial.

Standard of Care Arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: Adults aged 18 years and older. Condition: Patients who have undergone Mohs surgery on the scalp. Consent: Ability to provide informed consent. Willingness to Participate: Willingness to comply with study procedures and attend follow-up visits.
• Healing by Secondary Intention: Wounds intended to heal by secondary intention.

You may not qualify if:

• Known allergy or sensitivity to timolol or any components of the study medication.
• Bronchial asthma or history of bronchial asthma
• Severe chronic obstructive pulmonary disease (COPD)
• Sinus bradycardia
• Second or third-degree atrioventricular block
• Overt heart failure
• Cardiogenic shock
• Under the influence of opioids or benzodiazepines at time of enrollment
• History of scarring alopecia in area of Mohs wound
• History of radiation treatment
• Patients being treated for recurrent tumors

Sponsors & Collaborators

• Geisinger Clinic: lead

Study Sites (1)

Geisinger Dermatology Woodbine

Danville, Pennsylvania, 17821, United States

Location

MeSH Terms

Conditions

Surgical Wound; Cicatrix

Interventions

Timolol; Saline Solution

Condition Hierarchy (Ancestors)

Wounds and Injuries; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Propanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Propanols; Amines; Thiadiazoles; Thiazoles; Sulfur Compounds; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Morpholines; Oxazines; Crystalloid Solutions; Isotonic Solutions; Solutions; Pharmaceutical Preparations

Study Officials

• Amrit Greene, MD

  Geisinger Clinic

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael Woodfin, MD

CONTACT

570-271-8050; mwwoodfin1@geisinger.edu

Amrit Greene, MD

CONTACT

570-271-8050; agreene2@geisinger.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Physician

Study Record Dates

• First Submitted: May 7, 2026
• First Posted: May 13, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): July 1, 2028
• Study Completion (Estimated): March 1, 2029
• Last Updated: May 13, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)